LUIS ALBERTO DE PADUA COVAS LAGE

(Fonte: Lattes)
Índice h a partir de 2011
5
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/31 - Laboratório de Genética e Hematologia Molecular, Hospital das Clínicas, Faculdade de Medicina

Resultados de Busca

Agora exibindo 1 - 2 de 2
  • article 2 Citação(ões) na Scopus
    Treatment outcomes of adult Burkitt lymphoma: results with a modified LMB protocol in Brazil and feasibility of outpatient administration
    (2018) SILVA JUNIOR, Wellington Fernandes da; ROSA, Lidiane Ines da; BELESSO, Marcelo; LAGE, Luis Alberto P. C.; ROCHA, Vanderson; PEREIRA, Juliana
    While Burkitt lymphoma (BL) is an aggressive subtype of non-Hodgkin lymphoma more prevalent in tropical areas, few studies on BL have been conducted in Latin America. Here, we evaluate the clinical presentation and outcomes of an adapted LMB regimen for adults with sporadic BL. We retrospectively evaluated hospital records from University of Sao Paulo (USP) between 1999 and 2017. Thirty-six patients were included, the median age was 33.5 years and 69% (25) were male. Most patients presented advanced stage disease (81%), 8% had CNS disease, and the majority belonged to LMB group B (75% (27)). Three patients died during the induction phase, and the remaining patients (33) achieved complete response. There was one relapse over a median follow-up of 6 years. Overall survival estimated at 5 years was 89%. We conclude that an adapted LMB protocol is safe and feasible in Brazil.
  • article 4 Citação(ões) na Scopus
    FOXP3-positive T-cell lymphomas in non-HTLV1 carriers include ALK-negative anaplastic large cell lymphoma: expanding the spectrum of T-cell lymphomas with regulatory phenotype
    (2018) FERREIRA, Cristiane R.; ZHAO, Shuchun; SAHOO, Malaya K.; PINSKY, Benjamin; WEBER, Jenna; LAGE, Luis A. P. C.; PEREIRA, Juliana; ZERBINI, Maria C. N.; NATKUNAM, Yasodha
    Forkhead box P3 (FOXP3) is a specific marker for regulatory T-cells (Tregs). We report 6 cases of T-cell lymphomas with Treg phenotype based on diffuse positivity for FOXP3 in tumor cells. The patients showed a median age of 56 years with a male predominance. Sites of disease included lymph nodes (4), skin (2), subcutaneous tissue (1) and bone marrow (1). All cases showed monomorphic large cells, some with Hodgkin-like or anaplastic cells. All cases expressed pan T-cell markers and lacked cytotoxic markers; one case showed diffuse PD1 staining. Only one case harbored human T-lymphotrophic virus (HTLV)-1 DNA within tumor cells and was classified as adult T-cell leukemia/lymphoma (ATLL). Among 5 HTLV1-negative cases, 3 were classified as peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) and 2 fulfilled criteria for ALK-negative anaplastic large cell lymphoma (ALCL) with diffuse and strong CD30 positivity. We concluded that Treg phenotype may be rarely seen in HTLV1-negative cases, such as PTCL, NOS and ALK-negative ALCL. Our findings expand the spectrum of T-cell lymphomas with regulatory phenotype and suggest that consideration should be given to HTLV1 DNA testing in the appropriate clinical setting to rule out ATLL.